Cyclin D2 Promotes the Proliferation of Human Mesenchymal Stem CellsKen Kono, Shingo Niimi and Rumi Sawada*
Division of Medical Devices, National Institute of Health Sciences, Japan
- Corresponding Author:
- Rumi Sawada
Division of Medical Devices
National Institute of Health Sciences
1-18-1 Kamiyoga, Setagaya-ku
Tokyo 158-8501, Japan
E-mail: [email protected]
Received date: October 24, 2013; Accepted date: December 26, 2013; Published date: December 28, 2013
Citation: Kono K, Niimi S, Sawada R (2013) Cyclin D2 Promotes the Proliferation of Human Mesenchymal Stem Cells. J Bone Marrow Res 2:136. doi:10.4172/2329-8820.1000136
Copyright: © 2013 Kono K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Human mesenchymal stem cells (hMSCs) hold promise for use in cell-based therapies and tissue engineering. Although hMSCs are thought to be stable ex vivo, it is possible that they undergo an undesirable transformation to a phenotype of unlimited proliferation during ex vivo. In this study, we searched for the factor required for unlimited proliferation of hMSCs. Methods: Changes in gene expression were evaluated between hMSCs and Ewing’s sarcoma cell lines, which may be derived from hMSCs, using GeneChip Human Genome U133 plus 2.0 Array. A gene up-regulated by at least 10-fold in Ewing’s sarcoma cell lines, Cyclin D2, was overexpressed in hMSCs by a lentiviral vector. Results: Overexpression of Cyclin D2 in hMSCs altered cell morphology and promoted cell proliferation. Expression of transforming growth factor-b2 (TGF-b2), which induces senescence in hMSCs, was down-regulated in Cyclin D2- overexpressing hMSCs. Furthermore, Gene Ontology analysis revealed that Cyclin D2 overexpression activated expression of genes associated with proliferation and interphase. Conclusions: Cyclin D2 promotes hMSC proliferation and is a candidate biomaker for hMSC transformation.